Manning & Napier Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Manning & Napier Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78K	Buy	+38	New	+$1.82K	﹤0.01%	760

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Manning & Napier Advisors's SUPN Position: Q2 2026 in Review

Manning & Napier Advisors opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 38 shares worth $1.78K. The stake represents ﹤0.01% of the portfolio and ranks #760 among its holdings.

332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Manning & Napier Advisors held 38 shares of Supernus Pharmaceuticals worth $1.78K as of Q2 2026.
Supernus Pharmaceuticals was a new Manning & Napier Advisors position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #760 holding.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.